Akebia Therapeutics (AKBA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Si ...

Core Viewpoint - Regions Financial (RF) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is effective for individual investors as it focuses on earnings estimate revisions, which are strongly correlated with near-term stock price movements [2][4]. - An increase in earnings estimates typically leads to buying pressure from institutional investors, resulting in stock price increases [4][5]. Recent Performance and Projections - For the fiscal year ending December 2025, Regions Financial is expected to earn $2.26 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 2.3% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Regions Financial's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Kiora Pharmaceuticals, Inc. (KPRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following yea ...

Investors might want to bet on Corteva, Inc. (CTVA) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a ...

East West Bancorp (EWBC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since ...

Investors might want to bet on Taysha Gene Therapies, Inc. (TSHA) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since ...

Plumas Bancorp (PLBC) came out with quarterly earnings of $1.05 per share, missing the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.50%. A quarter ago, it was expected that this company would post earnings of $1.13 per share when it actually produced earnings of $1.2, delivering a surprise of +6.19%.Over the last four quarters, the company ha ...

Ferrari (RACE) is a Zacks Rank #1 (Strong Buy) that has an D for Value and an A for Growth. A recent earnings beat has this stock in the spotlight. This luxury auto maker will report earnings again at the end of the month and with the economy remaining resilient we might see a boost in sales. If that continues the stock will grow into is rather high valuation.  Let’s learn more about why this stock is the Bull of the Day.Description                                               Ferrari NV is a holding compa ...

The price trend for TIM S.A. Sponsored ADR (TIMB) has been bearish lately and the stock has lost 6.4% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Stree ...

BioMarin Pharmaceutical (BMRN) closed the last trading session at $56.62, gaining 3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $96.69 indicates a 70.8% upside potential.The mean estimate comprises 26 short-term price targets with a standard deviation of $14.53. While the lowest estimate of $65.00 indicates a 14.8% increase from the current price level, the most optimistic ana ...